Pfizer Opts to End Tripos Collaboration; Informatics Business Not Affected | GenomeWeb

NEW YORK, Nov. 25 (GenomeWeb News) - 

Tripos said last week that Pfizer will not renew a four-year file-enrichment collaboration that began in 2001.

Tripos received around $90 million over the project, in which it designed, synthesized, and purified a library of drug-like compounds for the pharmaceutical firm. The collaboration will end next month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.